DK3612174T3 - Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af sygdomme associeret med reduceret cftr-funktion - Google Patents

Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af sygdomme associeret med reduceret cftr-funktion Download PDF

Info

Publication number
DK3612174T3
DK3612174T3 DK18717946.0T DK18717946T DK3612174T3 DK 3612174 T3 DK3612174 T3 DK 3612174T3 DK 18717946 T DK18717946 T DK 18717946T DK 3612174 T3 DK3612174 T3 DK 3612174T3
Authority
DK
Denmark
Prior art keywords
treatment
methods
pharmaceutical compositions
diseases associated
cftr function
Prior art date
Application number
DK18717946.0T
Other languages
English (en)
Inventor
Pascal Trouve
Claude Ferec
Mathieu Kerbiriou
Florentin Huguet
Original Assignee
Inst Nat Sante Rech Med
Univ Bretagne Occidentale
Etablissement Francais Du Sang Efs
Centre Hospitalier Regional Et Univ De Brest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Bretagne Occidentale, Etablissement Francais Du Sang Efs, Centre Hospitalier Regional Et Univ De Brest filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK3612174T3 publication Critical patent/DK3612174T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK18717946.0T 2017-04-21 2018-04-20 Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af sygdomme associeret med reduceret cftr-funktion DK3612174T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305459 2017-04-21
PCT/EP2018/060145 WO2018193075A1 (en) 2017-04-21 2018-04-20 Methods and pharmaceutical compositions for the treatment of diseases associated with reduced cftr function

Publications (1)

Publication Number Publication Date
DK3612174T3 true DK3612174T3 (da) 2023-05-08

Family

ID=58640804

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18717946.0T DK3612174T3 (da) 2017-04-21 2018-04-20 Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af sygdomme associeret med reduceret cftr-funktion

Country Status (4)

Country Link
US (1) US11458118B2 (da)
EP (1) EP3612174B1 (da)
DK (1) DK3612174T3 (da)
WO (1) WO2018193075A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534423B2 (en) * 2019-01-03 2022-12-27 Washington University Methods and compositions for improving exercise endurance, performance, or tolerance

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6723553B2 (en) * 2000-06-27 2004-04-20 Biovitrum Ab Promoter sequences
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
PT2800811T (pt) 2012-05-25 2017-08-17 Univ California Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products

Also Published As

Publication number Publication date
EP3612174B1 (en) 2023-02-22
EP3612174A1 (en) 2020-02-26
US11458118B2 (en) 2022-10-04
WO2018193075A1 (en) 2018-10-25
US20200121642A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
DK3717471T3 (da) Nye forbindelser og lægemiddelsammensætninger heraf til behandling af sygdomme
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK3402499T3 (da) Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
DK3173092T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
DK3402888T3 (da) Middel og fremgangsmåder til behandling af hbv
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3487505T3 (da) Indgivelse og dosering af diaminophenothiaziner
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3386523T3 (da) Bifidobacterium longum til behandling af fedme og associerede metabolske sygdomme
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
DK3380525T3 (da) Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
DK3478679T3 (da) 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
DK3139963T3 (da) Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3122743T3 (da) Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme